These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 15714261)

  • 1. Pricing and welfare implications of parallel imports in the pharmaceutical industry.
    Jelovac I; Bordoy C
    Int J Health Care Finance Econ; 2005 Mar; 5(1):5-21. PubMed ID: 15714261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parallel imports and the pricing of pharmaceutical products: evidence from the European Union.
    Ganslandt M; Maskus KE
    J Health Econ; 2004 Sep; 23(5):1035-57. PubMed ID: 15353192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The welfare impact of parallel imports: a structural approach applied to the German market for oral anti-diabetics.
    Duso T; Herr A; Suppliet M
    Health Econ; 2014 Sep; 23(9):1036-57. PubMed ID: 25139795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deadweight loss of bacterial resistance due to overtreatment.
    Elbasha EH
    Health Econ; 2003 Feb; 12(2):125-38. PubMed ID: 12563660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential pricing for pharmaceuticals: reconciling access, R&D and patents.
    Danzon PM; Towse A
    Int J Health Care Finance Econ; 2003 Sep; 3(3):183-205. PubMed ID: 14625999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What price competitiveness in the drugs industry?
    Lancet; 2003 Jul; 362(9380):257. PubMed ID: 12892949
    [No Abstract]   [Full Text] [Related]  

  • 7. Parallel imports, price controls, and innovation.
    Reisinger M; Saurí L; Zenger H
    J Health Econ; 2019 Jul; 66():163-179. PubMed ID: 31202122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The London Agreement and the future of parallel imports.
    Muir J
    Nat Biotechnol; 2008 Aug; 26(8):877-9. PubMed ID: 18688237
    [No Abstract]   [Full Text] [Related]  

  • 9. The dilemma of intellectual property rights for pharmaceuticals: the tension between ensuring access of the poor to medicines and committing to international agreements.
    Cohen JC; Illingworth P
    Dev World Bioeth; 2003 May; 3(1):27-48. PubMed ID: 14577451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endogenous versus exogenous generic reference pricing for pharmaceuticals.
    Antoñanzas F; Juárez-Castelló CA; Rodríguez-Ibeas R
    Int J Health Econ Manag; 2017 Dec; 17(4):413-432. PubMed ID: 28508248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parallel imports and a mandatory substitution reform: a kick or a muff for price competition in pharmaceuticals?
    Granlund D; Koksal-Ayhan MY
    Eur J Health Econ; 2015 Dec; 16(9):969-83. PubMed ID: 25404013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Price regulation of pharmaceuticals in Canada.
    Anis AH; Wen Q
    J Health Econ; 1998 Jan; 17(1):21-38. PubMed ID: 10176313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Should the patent system for pharmaceuticals be replaced? A theoretical approach.
    Antoñanzas F; Rodríguez-Ibeas R; Juárez-Castelló CA
    Expert Rev Pharmacoecon Outcomes Res; 2014 Oct; 14(5):617-26. PubMed ID: 24934980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The market for pharmaceuticals.
    Bergenheim K; Braun U
    Dev Health Econ Public Policy; 1998; 7():187-208. PubMed ID: 10538829
    [No Abstract]   [Full Text] [Related]  

  • 15. A Study of Comparative Advantage and Intra-Industry Trade in the Pharmaceutical Industry of Iran.
    Yusefzadeh H; Rezapour A; Lotfi F; Ebadifard Azar F; Nabilo B; Abolghasem Gorji H; Hadian M; Shahidisadeghi N; Karami A
    Glob J Health Sci; 2015 Apr; 7(6):295-307. PubMed ID: 26153184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reference pricing of pharmaceuticals.
    Brekke KR; Königbauer I; Straume OR
    J Health Econ; 2007 May; 26(3):613-42. PubMed ID: 17188769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. International trade and determinants of price differentials of insulin medicine.
    Helble M; Aizawa T
    Health Policy Plan; 2017 Feb; 32(1):1-10. PubMed ID: 27346189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The consumer welfare implications of governmental policies and firm strategy in markets for medicines.
    Chatterjee C; Kubo K; Pingali V
    J Health Econ; 2015 Dec; 44():255-73. PubMed ID: 26581076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In search of a corrected prescription drug elasticity estimate: a meta-regression approach.
    Gemmill MC; Costa-Font J; McGuire A
    Health Econ; 2007 Jun; 16(6):627-43. PubMed ID: 17238227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parallel imports under a manufacturer rebate and a price freeze: Evidence from Germany.
    Birg L
    Health Econ; 2023 Feb; 32(2):302-323. PubMed ID: 36336829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.